Antithrombin III: The Serpin That Sets the Baseline of Coagulation Control

What Antithrombin III Is and Where It Comes From

Antithrombin III, also called AT-III or simply antithrombin, is a glycoprotein synthesized mainly in the liver. It belongs to the serine protease inhibitor family, known as serpins.

Hepatic synthesis is the dominant source, but it is not the only one. Lung, kidney, heart, spleen, intestine, and brain tissue can also produce antithrombin.

The protein circulates in two forms. Alpha-AT accounts for about 90% of the total, and beta-AT for about 10%. Both are measured together in most activity assays.

The Serpin Mechanism

Antithrombin carries a reactive center loop that acts as bait. When the loop engages the serine active site of a target protease, the two form a stable complex, and the protease is inhibited irreversibly.

The target list covers the central amplification steps of coagulation. Factors IXa, Xa, XIa, and XIIa are inhibited directly, and so is the complex formed by factor VIIa with tissue factor.

That breadth explains its position in the cascade. Antithrombin provides 70% to 80% of the physiological anticoagulant activity in plasma, which makes it the main brake on clot formation. When its level falls or its function is impaired, the balance tips toward hypercoagulability, and the risk of venous thrombosis and pulmonary embolism rises.

Antigen Level and Activity Are Different Measurements

Two assay families are used in practice. Immunological methods quantify how much antithrombin protein is present. Functional methods quantify how effectively it inhibits thrombin once heparin is available. The distinction matters most in type II deficiency, where the protein is present in normal amounts but performs poorly, so only a functional assay detects the defect. Reporting antigen and activity together is the safest approach whenever a deficiency is suspected.

Proposed mechanism of the antithrombin III–heparin system, showing thrombin, antithrombin III and heparin with the lysine, arginine and serine interaction sites

Why Heparin Needs Antithrombin

Heparin does not inhibit clotting factors on its own. It works by binding lysine residues on antithrombin and changing its conformation, which exposes arginine residues that engage the serine residue of thrombin more readily.

Once the heparin–antithrombin–thrombin complex forms, heparin dissociates and can be reused. Through this catalytic role, heparin can increase antithrombin activity by more than 2,000-fold.

Activity Thresholds That Change Heparin Dosing

The relationship between antithrombin activity and heparin response is steep and clinically actionable.

These thresholds are the reason antithrombin measurement often precedes or accompanies heparin therapy rather than following it.

Interpreting Abnormally High or Low Values

Elevated Antithrombin III

Elevated levels have been reported in hemophilia A and hemophilia B, during oral anticoagulant therapy, and with progesterone-class drugs. In each case the finding is a laboratory association rather than a direct consequence of the treatment. An isolated high value is therefore read alongside the clinical picture, not on its own.

Physiological Decreases That Are Not Disease

Several normal states lower antithrombin. Infants under six months have relatively low levels. Levels also fall after the thirteenth week of pregnancy and again postpartum. Before menopause, the average value in women is lower than in men.

Hereditary Deficiency

Hereditary antithrombin III deficiency follows an autosomal dominant pattern, with an estimated frequency of about 1 in 5,000. Presentation typically falls between 10 and 25 years of age, and thrombotic events cluster around surgery, trauma, infection, pregnancy, or the postpartum period.

Two subtypes are distinguished. In type I, antigen level and activity decrease in parallel. In type II, the antigen level is preserved but the protein is structurally abnormal, so activity alone reveals the defect.

Acquired Deficiency

Acquired deficiency arises through three routes. Reduced synthesis occurs in liver disease and tracks with disease severity. Increased loss occurs in nephrotic syndrome. Increased consumption occurs in thrombotic disease, disseminated intravascular coagulation, the postoperative period, oral contraceptive use, and pregnancy-induced hypertension.

Clinical Settings Where Monitoring Matters

Cerebrovascular Disease

Regular measurement of antithrombin activity supports early detection of a hypercoagulable state. That detection allows anticoagulant therapy to start before an acute cerebral infarction develops.

Cardiac Disease

Antithrombin activity is reduced in acute myocardial infarction, coronary heart disease, and atrial fibrillation. The reduction has been linked to endothelial injury and antithrombin consumption, so these patients warrant close monitoring.

Liver Disease Assessment

Because the liver is the principal production site, antithrombin activity reflects the degree of hepatic impairment. It serves as a sensitive indicator of how far liver pathology has progressed.

Kidney Disease

Measuring antithrombin before hemodialysis helps assess residual anticoagulant capacity and the expected response to heparin, which in turn informs the treatment plan.

Acute Infection and Sepsis

In sepsis, antithrombin activity can fall to 20% to 40% of normal. Changes in that value track disease progression, and early supplementation has been proposed to interrupt the development of disseminated intravascular coagulation and reduce mortality.

Pregnancy-Induced Hypertension

Women with pregnancy-induced hypertension show lower antithrombin activity than women with uncomplicated pregnancies, which indicates increased thrombotic risk. Antenatal monitoring is therefore relevant to both maternal and fetal safety.

Reference Reagents for Antithrombin III Research

Protein and antibody formats are available for assays that require purified antigen or specific detection. Products are listed in article order.

Key Features

ANT BIO PTE. LTD. provides supporting documentation for antithrombin III detection and coagulation research. Contact us for technical details or to request a sample test.

Summary

Antithrombin III is the single largest contributor to plasma anticoagulant capacity, and its serpin mechanism explains why heparin therapy fails when activity is low. Hereditary deficiency and acquired deficiency produce the same clinical risk through different routes, and both are detectable before a thrombotic event if activity is measured. The practical value of the assay lies in that lead time, whether the setting is cerebrovascular risk, cardiac disease, liver assessment, hemodialysis planning, sepsis, or pregnancy.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.